PTO/SB/08 A (08-03) Approved for use through 07/31/2006, OMB 0651-0031

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEP ARTMENT OF COMMERCE
or the paperwork Reduction Act of 1995, no nersons required to respond to a collection of information unless it constains valid OMR control number.

<i>\$</i> /				Complete if Known		
Substitute for form 1449/PTO				Application Number	10/509,464	
INFORMATION DISCLOSURE				Filing Date	September 27, 2004	
STATEM	STATEMENT BY APPLICANT			First Named Inventor	Christof Niehrs	
(Use as	(Use as many sheets as necessary)		Art Unit	1645 1647		
				Examiner Name	Unassigned J. Lockard	
Sheet	1	of	4	Attorney Docket Number	31301-702.831	

		U.S. PA	TENT DOC	UMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JL/	1	US- 2001/0036643 A1	11-01-2001	James L. Holloway	

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code' - Number' - Kind Code' ((f known) EP 0 911 399 A2	04-28-1999	Smithkline Beecham Corporation	recensive ignies Appeal	r
	3	WO 00/77239 A2	12-21-2000	Millennium Pharmaceuticials, Inc.		
	4	WO 01/34621 A1	05-17-2001	Human Genome Sciences, Inc.		
	5	WO 02/02603 A2	01-10-2002	Incyte Genomics, Inc.		Г
W	6	WO 02/066509 A2	08-29-2002	Genentech, Inc.		Г
/JL/	7	WO 02/092015 A2	11-21-2002	Genome Therapeutics		Г

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ΝU	8	BOYDEN, LYNN M PH.D. ET AL., High Bone Density Due to a Mutation in LDL-Receptor-related Protein 5, The New England Journal of Medicine, 2002, 346: 1513-1521	
/JL/	.9	BROWN SHERYL D ET AL, Isolation and Characterization of LRP6, a Novel Member of the Low Density Lipoprotein Receptor Gene Family, Biochemical and Biophysical Research Communications, 1998, 248: 879-888	

Examiner Signature	/Jon Lockard/	Date 04/11/2008	

^{*}EXAMINE: this if reference considered, whether or not classine is in conformance with MPE 469. Daw list through classine if not in conformance and not considered. Include copy of this form with next communication to neglectar. *Applicant* is support using existent or diseases and existent code (WIPO Standard ST J). *For Japanes to USFTO Patter Documents at www.upto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST J). *For Japanes parted documents, bit indication of the year of the relay of the letterpoor must preced the serial number of the patter document. *Wind of document by the appropriate symbols is indicated on the document used wIPO Standard ST 16 if possible. *Applicant is to place a check mark here if English language Translation is attached. USFTO by process) as application. Confidentially is governed by 38 USF. 212 and 37 CFR 1.14. This collection is entirated to take 2 hours to complete, including mount of the public which is to file (and by the USFTO by process) as application. Confidentially is governed by 38 USF. 212 and 37 CFR 1.14. This collection is entirated to take 2 hours to complete, including mount of USFTO application of the public wide is to file (and by the USFTO by process) as application. Confidentially is governed by 38 USFTO application of the complete good the tideful case. Application of the complete public wide is to file and by the USFTO application of the USFTO

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Con	nplete if Known
Substitute for form 1449/PTO				Application Number	10/509,464
INFORM	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	September 27, 2004
STATE				First Named Inventor	Christof Niehrs
(Use a	s many shee	ts as ne	cessary)	Art Unit	1645 1647
				Examiner Name	Unassigned J. Lockard
Sheet	1	of	4	Attorney Docket Number	31301-702.831

NON PATENT LITERATURE DOCUMENTS						
Examiner Cit Initials* No						
/JL/	10	DATABASE EMBL [Online] 26 June 2001 (2001-06-26), XP002249432 retrieved from EBI Database accession no. AAB95341				
	11	DATABASE EMBL [Online] 6 November 2001 (2001-11-06), XP002249370 retrieved from EBI Database accession no. AAM93480				
	12	FISCHER LESLIE ET AL, Wnt-3A Enhances Bone Morphogenectic Protein-2-medicated Chondrogenesis of Murine C3H10T1/2 Mesenchymal Cells, Journal of Biological Chemistry, 2002, 277: 30870-30878				
	13	FUJINO TAKAHIRO ET AL, Low-density Lipoprotein Receptor-related Protein 5 (LRP5) is Essential for Normal Cholesterol Metabolism and Glucose-Induced Insulin Secretion, Proc. Natl. Acad. Scie. U S A, 2003, 100: 229-234				
	14	GONG YAOQIN ET AL, LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development, Cell, 2001, 107: 513-523				
	15	KATO MASAKI ET AL, Cbfa1-Independent Decrease in Osteoblast Proliferation, Osteopenia, and Persistent Embryonic Eye Vascularization in Mice Deficient in Lrp5, a Wnt coreceptor, The Journal of Cell Biology, 2002, 157: 303-314				
/JL/	16	LITTLE RANDALL D. ET AL, A Mutation in the LDL Receptor-related Protein 5 Gene Results in the Autosomal Dominant High-Bone-Mass Trait, Am. J. Hum. Genet, 2002, 70: 11-19				

Examiner signature	/Jon Lockard/	Date Considered	04/11/2008	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

TEXAMINEX: Intuits it retirence consistence, writing for first in summariance was interest one, the many consistent in clusic decay of this form with next communication to applicant.

Applicant's unique clusion designation number (optional). Applicant is to place a clock mark here if English language Translation is statched.

This collection of information is required by 37 CFR 19.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 38 USC. 122 and 37 CFR 1.14. This collection is restimated to take 12 minutes to complex, including the complex of the collection of the collect aghering, perparing, and submitting the completed applysis-line form to the USPTO. Time will associated with the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this batter, and the time of the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this batter, should be part to the Chief Information Officer, US. Patient and Trackmark Office, P.O. Box 1463, Alexandrix, NA 233-1445. DO NOT SEND FEES OR OMPLETED FORMS TO THIS ASSESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute	for form 1449	PTO		Application Number	10/509,464	
INFORM	INFORMATION DISCLOSURE			Filing Date	September 27, 2004	
STATE	STATEMENT BY APPLICANT		First Named Inventor	Christof Niehrs		
(Use a	s many sheet	s as ne	cessary)	Art Unit	1645 1647	
				Examiner Name	Unassigned J. Lockard	
Sheet	1	of	4	Attorney Docket Number	31301-702.831	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/JL/	17	MAO BINGYU ET AL, LDL-receptor-related protein 6 is a receptor for Dickkopf Proteins, Nature, 2001, 411: 321-325	
	18	MILLER JEFFREY R. ET AL, Signal Transduction Through β-catenin and Specification of Cell Fate During Embryogenesis, Genes & Development, 1996, 10: 2527-2539	
	19	NAKAMURA TAKAHIRO ET AL, Molecular Cloning and Characterization of Kremen, a Novel Kringle-containing Transmembrane Protein, Biochimica et Biophysica Acta, 2001, 1518: 63-72	
	20	NUSSE ROEL ET AL, Wnt Genes, Cell, 1992, 69: 1073-1087	
	21	PEIFER MARK, β-Catenin as Oncogene: The Smoking Gun, Science, 1997, 275: 1752-1753	
	22	POLAKÍS PAUL, Wnt Signaling and Cancer, Genes & Development, 2000, 14: 1837-1851	
/JL/	23	SAADI-KHEDDOUCI SIHEM ET AL, Early Development of Polycystic Kidney Disease in Transgenic Mice Expressing an Activated Mutant of the β -catenin Gene, Oncogene, 2001, 20: 5972-5981	

Examiner signature	/Jon Lockard/	Date Considered	04/11/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached

This collection of Information is required by 37 CFR 19.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO

to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08 A (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE				Application Number	10/509,464	
			LOSURE	Filing Date	September 27, 2004	
STATEM	STATEMENT BY APPLICANT			First Named Inventor	Christof Niehrs	
(Use as	many shee	ts as nec	essary)	Art Unit	1645 1647	
				Examiner Name	Umssigned J. Lockard	
Sheet	1	of	4	Attorney Docket Number	31301-702.831	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/JL/	24	SURENDRAN KAMESWARAN ET AL, A Role for Wnt-4 in Renal Fibrosis, Am. J. Physiol. Renal Physiol., 2002, 282: 431-441	
	25	VAN ES JOHAN H ET AL, You Wnt some, you lose some: Oncogenese in the Wnt signaling pathway, Current Opinion in Genetics & Development, 2003, 13: 28-33	
	26	YANG YINGZI ET AL, Wnt5a and Wnt5b Exhibit Distinct Activities in Coordinating Chondrocyte Proliferation and Differentiation, Development, 2003, 130: 1003-1015	
/JL/	27	AARON M. ZORN, Wnt Signaling: Antagonistic Dickkopfs, Current Biology, 2001, 11: R592-595	

Examiner /Jon Lockard/ Date O4/11/2008 Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINE: Initial if reference considered, whether or not classion is in conformance with MPEP 669. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique cluston designation number (opinional). 'Applicant is to place a clock mark here if English language Translation is attached.

'Applicant's unique cluston designation number (opinional). 'Applicant is to place a clock mark here if English language Translation is attached.

This collection of Information is required by 39 J CFR 19.8. The direction is close that the place with the complete designation from the turber? In this collection is estimated to take 12 minutes to complete, including interference properties depicted and submitting the completed application from the turber? In line will vary depending upon the individual case. Any comments on the amount of time you require to complete distribution from the turber? In line will vary depending upon the individual case. Any comments on the amount of time you require to complete distribution from the turber of reducing the burden, should be sent to the Chief Information Officer. U.S. Patent and Translatural Office. On Don 183 MORES OR COMPLETED FORMST OT INIS ADDRESS. SEND TO